CR20110513A - Biomarcador para monitorear pacientes - Google Patents

Biomarcador para monitorear pacientes

Info

Publication number
CR20110513A
CR20110513A CR20110513A CR20110513A CR20110513A CR 20110513 A CR20110513 A CR 20110513A CR 20110513 A CR20110513 A CR 20110513A CR 20110513 A CR20110513 A CR 20110513A CR 20110513 A CR20110513 A CR 20110513A
Authority
CR
Costa Rica
Prior art keywords
biomarcator
monitor patients
immunotherapy
patients
monitor
Prior art date
Application number
CR20110513A
Other languages
English (en)
Spanish (es)
Inventor
Bruce Acres
Original Assignee
Ifco Systems Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ifco Systems Gmbh filed Critical Ifco Systems Gmbh
Publication of CR20110513A publication Critical patent/CR20110513A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001169Tumor associated carbohydrates
    • A61K39/00117Mucins, e.g. MUC-1
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • G01N33/505Cells of the immune system involving T-cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051T-cell receptor (TcR)-CD3 complex
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/7056Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CR20110513A 2009-04-17 2011-09-29 Biomarcador para monitorear pacientes CR20110513A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09305328 2009-04-17

Publications (1)

Publication Number Publication Date
CR20110513A true CR20110513A (es) 2012-01-06

Family

ID=42270292

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110513A CR20110513A (es) 2009-04-17 2011-09-29 Biomarcador para monitorear pacientes

Country Status (26)

Country Link
US (2) US20120058493A1 (enExample)
EP (1) EP2419728B1 (enExample)
JP (1) JP5661738B2 (enExample)
KR (1) KR20120027146A (enExample)
CN (1) CN102395883B (enExample)
AU (1) AU2010237215B2 (enExample)
BR (1) BRPI1010512A2 (enExample)
CA (1) CA2759050A1 (enExample)
CO (1) CO6440591A2 (enExample)
CR (1) CR20110513A (enExample)
CY (1) CY1114910T1 (enExample)
DK (1) DK2419728T3 (enExample)
ES (1) ES2445146T3 (enExample)
HR (1) HRP20140262T1 (enExample)
IL (1) IL214917A (enExample)
MX (1) MX2011010920A (enExample)
NZ (1) NZ594896A (enExample)
PL (1) PL2419728T3 (enExample)
PT (1) PT2419728E (enExample)
RU (1) RU2555340C2 (enExample)
SG (1) SG175060A1 (enExample)
SI (1) SI2419728T1 (enExample)
SM (1) SMT201400046B (enExample)
TW (1) TWI426270B (enExample)
WO (1) WO2010119003A1 (enExample)
ZA (1) ZA201107545B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6375947B2 (ja) * 2012-05-11 2018-08-22 味の素株式会社 取得方法、評価装置、評価方法、評価プログラム、評価システムおよび端末装置
US20140244556A1 (en) * 2013-02-27 2014-08-28 Abdul Saleh Methods for and apparatus generating automated pharmaco genetics correlation
US20200353107A1 (en) * 2017-12-08 2020-11-12 Stc.Unm In vivo imaging of tumor infiltration leukocytes
CN114859057A (zh) * 2022-04-13 2022-08-05 江苏省中医院 人结直肠癌或人结直肠癌转移的预测性生物标志物及其应用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
FR2643817B1 (fr) 1989-03-06 1993-12-17 Transgene Sa Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus
DE3642912A1 (de) 1986-12-16 1988-06-30 Leybold Ag Messeinrichtung fuer paramagnetische messgeraete mit einer messkammer
US6054438A (en) 1987-01-07 2000-04-25 Imperial Cancer Research Technology Limited Nucleic acid fragments encoding portions of the core protein of the human mammary epithelial mucin
FR2632863B2 (fr) 1987-10-29 1990-08-31 Transgene Sa Virus du fowlpox recombinant et vaccins derives de ces virus
US5100587A (en) 1989-11-13 1992-03-31 The United States Of America As Represented By The Department Of Energy Solid-state radioluminescent zeolite-containing composition and light sources
FR2668064B1 (fr) 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
US5756102A (en) 1990-11-20 1998-05-26 Virogenetics Corporation Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
AU672359B2 (en) 1991-03-07 1996-10-03 Virogenetics Corporation Genetically engineered vaccine strain
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5179993A (en) 1991-03-26 1993-01-19 Hughes Aircraft Company Method of fabricating anisometric metal needles and birefringent suspension thereof in dielectric fluid
US6013638A (en) 1991-10-02 2000-01-11 The United States Of America As Represented By The Department Of Health And Human Services Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung
US6133028A (en) 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5698443A (en) 1995-06-27 1997-12-16 Calydon, Inc. Tissue specific viral vectors
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
EP0772619B2 (en) 1994-07-15 2010-12-08 The University of Iowa Research Foundation Immunomodulatory oligonucleotides
US6045802A (en) * 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
US6638762B1 (en) 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
FR2727689A1 (fr) 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
DE19520606B4 (de) 1995-06-06 2004-04-08 Roche Diagnostics Gmbh Vorrichtung zur optischen Untersuchung von Oberflächen
EP1445322B2 (en) 1995-06-15 2012-06-06 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
WO1998004727A1 (en) 1996-07-25 1998-02-05 Therion Biologics Corporation Recombinant pox virus for immunization against tumor-associated antigens
FR2751879B1 (fr) 1996-07-30 1998-10-30 Transgene Sa Composition pharmaceutique contre les tumeurs et infections a papillomavirus
AU727308B2 (en) 1997-02-24 2000-12-07 Dana-Farber Cancer Institute Recombinant pox virus for immunization against muc1 tumor-associated antigen
FR2766091A1 (fr) 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
FR2773885B1 (fr) 1998-01-16 2000-03-03 Elf Antar France Methode de caracterisation de la capacite de neutralisation d'un lubrifiant et dispositif pour la mise en oeuvre de cette methode
JP3119228B2 (ja) 1998-01-20 2000-12-18 日本電気株式会社 液晶表示パネル及びその製造方法
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
US6900049B2 (en) 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
US20020037274A1 (en) 1998-10-26 2002-03-28 Angelica Williams Single agent method for killing tumor and tumor associated endothelial cells using adenoviral mutants
FR2787465A1 (fr) 1998-12-21 2000-06-23 Transgene Sa Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes
ES2220448T3 (es) 1999-02-04 2004-12-16 Geron Corporation Secuencias reguladoras de la transcripcion de la telomerasa transcriptasa inversa.
ATE332364T1 (de) 1999-02-22 2006-07-15 Transgene Sa Verfahren zur gewinnung von purifizierter virenzuammensetzung
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US7001596B1 (en) 1999-11-15 2006-02-21 Onyx Pharmaceuticals, Inc. Oncolytic adenovirus
AUPQ520800A0 (en) 2000-01-21 2000-02-17 Alfred Hospital Prime-boost vaccination strategy
DE20122302U1 (de) 2000-11-23 2005-02-24 Bavarian Nordic A/S Variante des Modifizierten Vaccinia-Ankara-Virus
FI116851B (fi) * 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
GB0118532D0 (en) 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
US20040133243A1 (en) 2002-07-26 2004-07-08 Santamore William P. Cardiac rhythm management system with intramural myocardial pacing leads and electrodes
MXPA05004588A (es) 2002-10-29 2005-12-14 Coley Pharmaceutical Group Ltd Metodos y productos relacionados con el tratamiento y prevencion de infeccion de virus de hepatitis c.
FR2862648B1 (fr) 2003-11-21 2006-02-03 Biomerieux Sa Nouveau peptide immunogene et nouveaux epitopes et utilisations notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l 'hepatite c
ES2526344T3 (es) * 2005-06-28 2015-01-09 Oncothyreon Inc. Método para el tratamiento de pacientes con una vacuna de glicoproteína mucinosa (MUC-1)
CN101541342A (zh) * 2006-12-05 2009-09-23 特朗斯吉有限公司 产生提高的免疫应答的手段和方法
BRPI0913108A2 (pt) * 2008-05-29 2017-06-20 Trangene S A método ex-vivo para testar se um paciente responderá terapeuticamente a um método de tratamento, uso de níveis de células exterminadores naturais ativadas como um biomarcador, e, kit

Also Published As

Publication number Publication date
WO2010119003A1 (en) 2010-10-21
BRPI1010512A2 (pt) 2016-03-15
HK1163246A1 (en) 2012-09-07
EP2419728B1 (en) 2014-01-08
SMT201400046B (it) 2014-05-07
ZA201107545B (en) 2012-07-25
ES2445146T3 (es) 2014-02-28
CN102395883A (zh) 2012-03-28
US20140141039A1 (en) 2014-05-22
NZ594896A (en) 2013-07-26
CY1114910T1 (el) 2016-12-14
SI2419728T1 (sl) 2014-03-31
EP2419728A1 (en) 2012-02-22
CO6440591A2 (es) 2012-05-15
SG175060A1 (en) 2011-11-28
TWI426270B (zh) 2014-02-11
PL2419728T3 (pl) 2014-05-30
RU2011146419A (ru) 2013-05-27
AU2010237215A1 (en) 2011-09-22
TW201040530A (en) 2010-11-16
JP2012524248A (ja) 2012-10-11
IL214917A (en) 2016-03-31
JP5661738B2 (ja) 2015-01-28
KR20120027146A (ko) 2012-03-21
US20120058493A1 (en) 2012-03-08
DK2419728T3 (da) 2014-02-03
MX2011010920A (es) 2011-11-04
HRP20140262T1 (hr) 2014-04-25
CN102395883B (zh) 2015-12-02
PT2419728E (pt) 2014-03-12
CA2759050A1 (en) 2010-10-21
RU2555340C2 (ru) 2015-07-10
IL214917A0 (en) 2011-11-30
AU2010237215B2 (en) 2014-05-01

Similar Documents

Publication Publication Date Title
MX391175B (es) Macrociclos peptidomimeticos.
BR112012000934A2 (pt) cassetes e métodos de utilizacao destes
CU20140025A7 (es) Pirimidinas anilladas sustituidas
IL229474A0 (en) Cannabinoids for use in the treatment of neuropatich pain
UY33863A (es) Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer
PT2613774T (pt) Combinação de fenoxibenzamina e polimixina e para tratar infeções microbianas
EP2797531A4 (en) ORTHOPEDIC COMPRESSION PLATE AND SURGICAL PROCEDURE
PT2523661T (pt) Inibidores de nkcc para o tratamento de autismo
CO7020878A2 (es) Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
IL226049A0 (en) Composition for use in the prevention and/or treatment of skin conditions and skin diseases
UY33271A (es) Inhibidores heterocíclicos de los receptores de histamina para el tratamiento de una enfermedad
PT2528946T (pt) Métodos de tratamento de doenças autoimunes com antagonistas de dll4
CR20110560A (es) Métodos de tratamiento para tumores sólidos
MX351464B (es) El uso de un agonista del receptor 8 tipo toll para el tratamiento de enfermedades alérgicas.
MX2011009690A (es) Métodos y composiciones para trastornos relacionados con la proliferación celurar.
CR20130517A (es) Tratamientos combinados para neoplasias hematológicas malignas
HRP20181378T1 (hr) Postupci liječenja pedijatrijskih pacijenata deksmedetomidinom
CR20120473A (es) Composiciones y métodos para el diagnóstico y tratamiento de tumores
CO6801724A2 (es) Composiciones y métodos para el tratamiento de la mielofibrosis
EP2920171A4 (en) PURINMER OF HUMAN PHOSPHATIDYLINOSITE-3-KINASE DELTA
PL2717692T3 (pl) Kwasy tetrahydrokannabinol-11-owe do stosowania w leczeniu chorób zwłóknieniowych
HRP20181599T1 (hr) Proizvodnja i upotreba bakterijskog histamina
UA111475C2 (uk) Способи лікування із застосуванням ліпідних сполук
CO7151543A2 (es) Combinaciones terapéuticas y métodos para tratar el melanoma
EA201201296A1 (ru) Способы лечения диабетических язв стопы